Amalgamated Bank’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.5M | Sell |
19,387
-861
| -4% | -$485K | 0.07% | 219 |
|
|
2026
Q1 | $12M | Buy |
20,248
+796
| +4% | +$396K | 0.09% | 177 |
|
|
2025
Q4 | $9.48M | Sell |
19,452
-1,312
| -6% | -$611K | 0.07% | 214 |
|
|
2025
Q3 | $8.7M | Buy |
20,764
+42
| +0.2% | +$14.1K | 0.06% | 238 |
|
|
2025
Q2 | $5.95M | Sell |
20,722
-538
| -3% | -$161K | 0.05% | 320 |
|
|
2025
Q1 | $6.55M | Sell |
21,260
-907
| -4% | -$311K | 0.06% | 276 |
|
|
2024
Q4 | $7.82M | Buy |
22,167
+602
| +3% | +$221K | 0.06% | 234 |
|
|
2024
Q3 | $7.73M | Sell |
21,565
-3,841
| -15% | -$1.3M | 0.06% | 252 |
|
|
2024
Q2 | $8.09M | Sell |
25,406
-2,173
| -8% | -$575K | 0.07% | 225 |
|
|
2024
Q1 | $6.33M | Sell |
27,579
-1,446
| -5% | -$326K | 0.05% | 342 |
|
|
2023
Q4 | $6.38M | Sell |
29,025
-820
| -3% | -$189K | 0.05% | 362 |
|
|
2023
Q3 | $6.74M | Sell |
29,845
-436
| -1% | -$100K | 0.06% | 306 |
|
|
2023
Q2 | $6.68M | Sell |
30,281
-1,735
| -5% | -$384K | 0.05% | 314 |
|
|
2023
Q1 | $7.17M | Sell |
32,016
-962
| -3% | -$237K | 0.06% | 290 |
|
|
2022
Q4 | $9.17M | Sell |
32,978
-83
| -0.3% | -$21K | 0.08% | 219 |
|
|
2022
Q3 | $6.92M | Buy |
33,061
+319
| +1% | +$71.3K | 0.07% | 267 |
|
|
2022
Q2 | $7.71M | Buy |
32,742
+1,158
| +4% | +$235K | 0.07% | 241 |
|
|
2022
Q1 | $5.67M | Sell |
31,584
-1,120
| -3% | -$213K | 0.04% | 410 |
|
|
2021
Q4 | $7.07M | Sell |
32,704
-1,347
| -4% | -$264K | 0.05% | 346 |
|
|
2021
Q3 | $6.29M | Sell |
34,051
-3,253
| -9% | -$641K | 0.05% | 372 |
|
|
2021
Q2 | $6.69M | Buy |
37,304
+31,881
| +588% | +$6.07M | 0.05% | 367 |
|
|
2021
Q1 | $907K | Sell |
5,423
-359
| -6% | -$59.9K | 0.03% | 636 |
|
|
2020
Q4 | $878K | Buy |
5,782
+15
| +0.3% | +$1.97K | 0.03% | 627 |
|
|
2020
Q3 | $582K | Sell |
5,767
-24
| -0.4% | -$2.63K | 0.03% | 758 |
|
|
2020
Q2 | $701K | Sell |
5,791
-3,966
| -41% | -$446K | 0.03% | 622 |
|
|
2020
Q1 | $925K | Sell |
9,757
-215
| -2% | -$20.4K | 0.02% | 651 |
|
|
2019
Q4 | $878K | Buy |
9,972
+1,049
| +12% | +$92.3K | 0.02% | 855 |
|
|
2019
Q3 | $712K | Sell |
8,923
-157
| -2% | -$12.6K | 0.02% | 887 |
|
|
2019
Q2 | $709K | Buy |
9,080
+456
| +5% | +$42.6K | 0.02% | 899 |
|
|
2019
Q1 | $1.01M | Buy |
8,624
+183
| +2% | +$21.3K | 0.02% | 706 |
|
|
2018
Q4 | $919K | Sell |
8,441
-118
| -1% | -$13.7K | 0.03% | 686 |
|
|
2018
Q3 | $1.09M | Sell |
8,559
-24
| -0.3% | -$2.97K | 0.03% | 635 |
|
|
2018
Q2 | $971K | Sell |
8,583
-22
| -0.3% | -$2.42K | 0.02% | 770 |
|
|
2018
Q1 | $967K | Sell |
8,605
-80
| -0.9% | -$10.2K | 0.03% | 717 |
|
|
2017
Q4 | $1.28M | Buy |
8,685
+489
| +6% | +$62.2K | 0.03% | 595 |
|
|
2017
Q3 | $960K | Sell |
8,196
-512
| -6% | -$65.4K | 0.03% | 672 |
|
|
2017
Q2 | $1.13M | Buy |
8,708
+1,683
| +24% | +$210K | 0.04% | 572 |
|
|
2017
Q1 | $951K | Sell |
7,025
-217
| -3% | -$32.9K | 0.05% | 461 |
|
|
2016
Q4 | $1.04M | Buy |
7,242
+790
| +12% | +$101K | 0.05% | 454 |
|
|
2016
Q3 | $762K | Sell |
6,452
-23
| -0.4% | -$2.76K | 0.04% | 501 |
|
|
2016
Q2 | $805K | Buy |
6,475
+799
| +14% | +$89.1K | 0.05% | 478 |
|
|
2016
Q1 | $632K | Buy |
5,676
+428
| +8% | +$54.2K | 0.06% | 402 |
|
|
2015
Q4 | $822K | Sell |
5,248
-365
| -7% | -$53.1K | 0.1% | 199 |
|
|
2015
Q3 | $737K | Buy |
5,613
+80
| +1% | +$12.8K | 0.08% | 299 |
|
|
2015
Q2 | $962K | Sell |
5,533
-99
| -2% | -$17.8K | 0.09% | 208 |
|
|
2015
Q1 | $971K | Buy |
5,632
+188
| +3% | +$28.7K | 0.12% | 191 |
|
|
2014
Q4 | $705K | Buy |
5,444
+8
| +0.1% | +$1.03K | 0.11% | 221 |
|
|
2014
Q3 | $699K | Buy |
5,436
+81
| +2% | +$8.35K | 0.1% | 226 |
|
|
2014
Q2 | $474K | Sell |
5,355
-90
| -2% | -$8.65K | 0.07% | 363 |
|
|
2014
Q1 | $512K | Sell |
5,445
-38
| -0.7% | -$3.89K | 0.09% | 311 |
|
|
2013
Q4 | $620K | Buy |
+5,483
| New | +$494K | 0.11% | 228 |
|
Other funds holding UTHR
Amalgamated Bank's UTHR Position: Q2 2026 in Review
Amalgamated Bank reduced its United Therapeutics (UTHR) stake by 4.3% in Q2 2026, selling an estimated $485K and leaving 19,387 shares worth $10.5M. The position accounts for 0.07% of the portfolio, ranked #219.
Amalgamated Bank first reported a position in UTHR in Q4 2013 and has held it in 51 quarters since. The position peaked at $12M in Q1 2026. 417 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Amalgamated Bank held 19,387 shares of United Therapeutics worth $10.5M as of Q2 2026.
- Amalgamated Bank sold 861 United Therapeutics shares in Q2 2026, an estimated $485K.
- United Therapeutics made up 0.07% of Amalgamated Bank's portfolio in Q2 2026, its #219 holding.
- Amalgamated Bank first reported a position in United Therapeutics in Q4 2013 and has held it in 51 quarters since.
- Amalgamated Bank's United Therapeutics position peaked at $12M in Q1 2026.
- 417 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.